A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  ACS Chemical Neuroscience

• Publication date

  2018-04-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acschemneuro.7b00469PMID 29614860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyloid Beta

  2019cited by this paper
• Fibril structure of amyloid-β(1–42) by cryo–electron microscopy

  2017cited by this paper
• Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data

  2017cited by this paper
• Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein

  2016cited by this paper
• Alzheimer’s and other dementias in Canada, 2011 to 2031: a microsimulation Population Health Modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use

  2016cited by this paper
• Small Heat-shock Proteins Prevent α-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation*

  2016cited by this paper
• Complement and microglia mediate early synapse loss in Alzheimer mouse models

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease

  2016cited by this paper
• Alzheimer’s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression

  2016cited by this paper
• Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril

  2016cited by this paper
• Alzheimer’s and other dementias in Canada, 2011 to 2031: a microsimulation Population Health Modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use

  2016cited by this paper
• High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification

  2015cited by this paper
• On the lag phase in amyloid fibril formation

  2015cited by this paper
• Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration.

  2015cited by this paper
• The problem of genotype and sex differences in life expectancy in transgenic AD mice.

  2015cited by this paper
• Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

  2015cited by this paper
• Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models*

  2015cited by this paper
• Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s

  2015cited by this paper
• The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

  2014cited by this paper
• Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer's disease.

  2014cited by this paper
• Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cited by this paper
• Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight Aβ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers

  2013cited by this paper
• Molecular Structure of beta-Amyloid Fibrils in Alzheimer's Disease Brain Tissue.

  2013cited by this paper
• Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue.

  2013cited by this paper
• Faculty Opinions recommendation of Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils.

  2013cited by this paper
• Brain amyloid-β oligomers in ageing and Alzheimer's disease.

  2013cited by this paper
• Unfolded protein ensembles, folding trajectories, and refolding rate prediction.

  2013cited by this paper
• Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

  2013cited by this paper
• Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

  2013cited by this paper
• Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid

  2012cited by this paper
• Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b

  2012cited by this paper
• The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

  2012cited by this paper
• Amyloid-related imaging abnormalities (ARIA) in Alzheimer’sdisease patients treated with bapineuzumab: A retrospective analysis

  2012cited by this paper
• Sex and Gender Differences in Alzheimer's Disease: Recommendations for Future Research

  2012cited by this paper
• Toxic fibrillar oligomers of amyloid-β have cross-β structure

  2012cited by this paper
• Immunotherapy for Alzheimer disease—the challenge of adverse effects

  2012cited by this paper
• Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment

  2012cited by this paper
• Tetracycline prevents Aβ oligomer toxicity through an atypical supramolecular interaction.

  2011cited by this paper
• Molecular basis for amyloid-β polymorphism

  2011cited by this paper
• Structure-based design of conformation- and sequence-specific antibodies against amyloid β

  2011cited by this paper
• Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

  2011cited by this paper
• Administration of Amyloid-β42 Oligomer-Specific Monoclonal Antibody Improved Memory Performance in SAMP8 Mice

  2011cited by this paper
• P2‐478: A key role for lysine residues in amyloid‐β protein folding, assembly, and toxicity

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Amyloid‐beta oligomers increase the localization of prion protein at the cell surface

  2011cited by this paper
• How robust are protein folding simulations with respect to force field parameterization?

  2011cited by this paper
• Cognitive effects of cell-derived and synthetically derived Aβ oligomers.

  2011cited by this paper
• Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils

  2010cited by this paper
• Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

  2010cited by this paper
• Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers

  2010cited by this paper
• Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies

  2010cited by this paper
• Intracellular amyloid formation in muscle cells of Aβ-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification

  2009cited by this paper
• Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers

  2009cited by this paper
• Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.

  2009cited by this paper
• Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers

  2009cited by this paper
• Cued and Contextual Fear Conditioning for Rodents

  2009cited by this paper
• Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.

  2009cited by this paper
• Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.

  2008cited by this paper
• Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

  2008cited by this paper
• Amyloid Oligomer Conformation in a Group of Natively Folded Proteins

  2008cited by this paper
• An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS

  2007cited by this paper
• Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers

  2007cited by this paper
• Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate.

  2007cited by this paper
• Monoclonal antibodies that target pathological assemblies of Aβ

  2007cited by this paper
• Atomic structures of amyloid cross-beta spines reveal varied steric zippers.

  2007cited by this paper
• Amyloid β‐protein monomer structure: A computational and experimental study

  2006cited by this paper
• Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice*

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• High-resolution atomic force microscopy of soluble Abeta42 oligomers.

  2006cited by this paper
• On the nucleation of amyloid beta-protein monomer folding.

  2005cited by this paper
• 3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

  2005cited by this paper
• Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

  2005cited by this paper
• Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.

  2004cited by this paper
• Current progress in beta-amyloid immunotherapy.

  2004cited by this paper
• A prion protein epitope selective for the pathologically misfolded conformation

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Sensitivity enhancement in structural measurements by solid state NMR through pulsed spin locking.

  2002cited by this paper
• A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR.

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Impact of Engineering Students' Attitudes on Achievement in Statistics: A Structural Model

  2002cited by this paper
• All-atom empirical force field for nucleic acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data

  2000cited by this paper
• All-atom empirical potential for molecular modeling and dynamics studies of proteins.

  1998cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.

  1989cited by this paper
• The clinical diagnosis of Alzheimer's disease.

  1987cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect.

  1984cited by this paper
• Comparison of simple potential functions for simulating liquid water

  1983cited by this paper
• Analytical molecular surface calculation

  1983cited by this paper

• De novo design of a β-helix tau protein scaffold: An oligomer-selective vaccine immunogen candidate for Alzheimer’s disease

  2023cites this paper
• ANTI-AMYLOID-BETA OLIGOMER ANTIBODY INCREASES THE SURVIVAL OF NEWBORN HIPPOCAMPAL NEURONS

  2023influential citation
• Accelerated ensemble generation for cyclic peptides using a Reservoir-REMD implementation in GROMACS

  2022cites this paper
• The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease

  2022cites this paper
• Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure

  2022cites this paper
• Ensemble Generation for Linear and Cyclic Peptides Using a Reservoir Replica Exchange Molecular Dynamics Implementation in GROMACS.

  2022cites this paper
• Testing the link between isoaspartate and Alzheimer’s disease etiology

  2022cites this paper
• Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity

  2021cites this paper
• A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria

  2021cites this paper
• Epitope scaffolding using α-synuclein cyclic peptides to generate oligomer-selective antibodies for Parkinson’s disease

  2021cites this paper
• Optimizing Epitope Conformational Ensembles Using α-Synuclein Cyclic Peptide “Glycindel” Scaffolds: A Customized Immunogen Method for Generating Oligomer-Selective Antibodies for Parkinson’s Disease

  2021cites this paper
• Structure Dependent Differential Modulation of Aβ Fibrillization by Selenadiazole-Based Inhibitors.

  2021cites this paper
• Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

  2020cites this paper
• Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates

  2020cites this paper
• Visualizing and trapping transient oligomers in amyloid assembly pathways

  2020cites this paper
• Harmony of T cell profile in brain, nasal, spleen, and cervical lymph nodes tissues in Alzheimer's: A systemic disease with local manifestations.

  2020cites this paper
• Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

  2019cites this paper
• Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases

  2019cites this paper
• A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

  2019cites this paper
• Prediction of Misfolding-Specific Epitopes in SOD1 Using Collective Coordinates.

  2018cites this paper